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osmolality (r = −0.479, p = 0.038), the baseline urine vol-
ume (r = −0.48, p = 0.028), and the baseline inferior vena 
cava diameter (IVCD) (r = −0.622, p = 0.017). Hypona-
tremia was improved to the normal value, and the augmen-
tations of the sodium concentration were negatively associ-
ated with the basal sodium levels (p = 0.01, r = −0.546).
Conclusions Tolvaptan is effective in increasing diuresis 
and improved hyponatremia, even in patients with CKD. 
The baseline urine osmolality, urine volume, and IVCD 
may be useful predictors for diuretic effects of tolvaptan.
Keywords Chronic kidney disease · Tolvaptan · Urine 
osmolality · Hyponatremia
Introduction
Tolvaptan is an oral diuretic with a new mechanism which 
selectivity binds to the  V2 receptor as an antagonist.  V2 
receptors are located in the renal collecting duct, where 
arginine vasopressin (AVP) binding to the  V2 receptor 
leads to a rise in intracellular cAMP. This promotes renal 
water reabsorption via translocation of intracellular vesi-
cles containing the water channel aquaporin-2 into the 
apical plasma membrane and increased transcription of 
aquaporin-2 [1]. The compound’s aquaretic effects by sin-
gle administration were confirmed by an increase in urine 
volume and a decrease in urine osmolality, followed by 
an increase in serum sodium concentration [2]. Tolvaptan 
has been demonstrated to ameliorate congestion in patients 
with heart failure [3, 4] and to correct hyponatremia [5, 6].
Patients with advanced CKD cannot produce enough 
urine and often fall into volume overload. Loop diuretics 
are conventionally used for these patients. However, there 
are several adverse effects with taking loop diuretics. One 
Abstract 
Background Tolvaptan, a vasopressin  V2 receptor blocker, 
has a diuretic effect for patients with heart failure. How-
ever, there were a few data concerning the effects of tolvap-
tan in patients with chronic kidney disease (CKD).
Methods We retrospectively analyzed 21 patients with 
chronic heart failure and CKD. Tolvaptan was co-admin-
istered with other diuretics in-use, every day. We com-
pared clinical parameters before and after the treatments 
with tolvaptan. Furthermore, we examined the correlations 
between baseline data and the change of body weight.
Results Tolvaptan decreased the body weight and 
increased the urine volume (p = 0.001). The urine osmo-
lality significantly decreased throughout the study period. 
Urinary Na/Cr ratio and FENa changed significantly after 
4  h, and more remarkable after 8  h (p = 0.003, both). 
Serum creatinine increased slightly after 1  week of treat-
ment (p = 0.012). The alteration of body weight within the 
study period correlated negatively with the baseline urine 
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is electrolyte abnormalities, such as hypokalemia and 
hyponatremia [7]. On the other hand, tolvaptan has been 
reported to promote water excretion without changes in 
renal hemodynamics or sodium and potassium excretion 
[1].
However, the effects of tolvaptan on urine volume, and 
urinary and serum sodium excretions in advanced CKD 
patients were not yet clarified. Furthermore, the parameters 
which relate to body weight reduction were also not suffi-
ciently evaluated. Thus, to clarify the effects of tolvaptan 
on body weight, and urinary and serum electrolytes, as well 
as to examine the predictors for efficacy, we retrospectively 
evaluated the medical records of CKD patients.
Materials and methods
Study subjects
This was a retrospective observational study. We included 
patients with CKD stage G3–5 and congestive heart failure, 
who were admitted to our hospital and received tolvaptan 
for excess body fluid, despite administration of the conven-
tional diuretics between December 2010 and April 2015. 
The definition of CKD G3–5 was eGFR less than 60  ml/
min/1.73 m2 over 3 months despite the underlying disease. 
We excluded the following: patients undergoing hemodi-
alysis and peritoneal dialysis, those whose dose of other 
diuretics increased during the observation period (3 days 
before and a week after tolvaptan administration), and a 
case of acute kidney injury. The initial tolvaptan dose was 
15 mg/day, except one case that started at 3.75 mg/day.
Measurements
The main endpoints of this study were changes of body 
weight after 1  week administration of tolvaptan, and we 
compared average urine volume for 3 days before and for 
7 days after treatment. In addition, we compared values of 
blood pressure, urine osmolality, urine gravity, urea sodium 
excretion calculated by spot urine (U-Na, mEq/gCr), frac-
tional excretion of sodium (FENa), serum creatinine, esti-
mated glomerular filtration rate (eGFR), serum sodium, 
B-type natriuretic peptide (BNP), human atrial natriuretic 
peptide (hANP), and antidiuretic hormone (ADH) before 
and after the administration of tolvaptan. We obtained data 
of urine osmolality, urine gravity, U-Na, and FENa after 
tolvaptan treatment at 4, 8, and 24  h. eGFR was calcu-
lated using the equation proposed by the Japanese Society 
of Nephrology as follows ; eGFR (ml/min/1.73  m2) = 194 
× Cr− 1.094 × Age−0.287×0.739 (if female) [8]. We collected 
data of the ejection fraction and inferior vena cava diam-
eter (IVCD) in the case that heart ultrasonography was 
performed before beginning tolvaptan. IVCD was visual-
ized two-dimensionally and measured by M-mode echocar-
diography in expiration as described elsewhere [9]. In cases 
of discharge or drug interruption, the data at discontinu-
ance were substituted.
Statistical analysis
The value of each measurement was expressed as the 
median (interquartile range). Comparisons of parameters 
between before and after treatment were analyzed with 
the Wilcoxon signed-rank test. Factors correlating with 
changes of body weight and S-Na were analyzed with the 
Spearman rank correlation coefficient. We considered a p 
value <0.05 as significant. Data analysis was performed 
with SPSS 23 statistical software (SPSS Inc., Chicago, IL, 
USA).
Results
Table 1 shows the clinical characteristics of the study sub-
jects. The study consisted of 15 men and 6 women with 
a median age of 69 (interquartile range 60–76). Nineteen 
patients were in CKD stage 5; two patients were in stage 
3a or 3b respectively. The median serum creatinine level 
just before administration of tolvaptan was 3.82  mg/dl 
(interquartile range 3.48–5.08). The average urine volume 
for 3 days before tolvaptan administration was distributed 
between 292 and 1900 ml/day, and the median of all cases 
was 975 ml/day. One patient was in NYHA IV and eleven 
patients were in NYHA III, and five were in NYHA II. Pri-
mary diseases included benign nephropathy (n = 10), dia-
betic nephropathy (n = 7), polycystic kidney disease (n = 1), 
microscopic polyangitis (n = 1), membranous nephropathy 
(n = 1), and lupus nephritis (n = 1). Patients were treated 
with the following diuretics: furosemide alone (median 
dose of 140  mg, interquartile range 80–200, n = 17), 
spironolactone 25  mg/day and trichlormethiazide 1  mg/
day (n = 1); furosemide 40 or 320  mg/day and potassium 
canrenoate 400  mg/day (n = 2); or spironolactone alone 
(25 mg/day, n = 1). The renin–angiotensin–aldosterone sys-
tem (RAAS) inhibitor was prescribed for 12 patients. Only 
1 patient took digitalis.
Body weight decreased (p < 0.001), and urine volume 
increased with tolvaptan treatment (p < 0.001) (Table  2). 
Reflecting water diuresis, urine osmolality decreased sig-
nificantly (Fig.  1a). The urine osmolality decreased after 
4  h (p = 0.001), and markedly at 8  h (p < 0.001). The 
effects on urine osmolality continued throughout the study 
periods. The urine gravity significantly decreased 8  h 
(p = 0.043, n = 6) and 24 h (p = 0.002, n = 14), but not sig-
nificant at 1 week (Table 2).
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U-Na and FENa increased significantly after 4  h 
(p = 0.035 and p = 0.022, respectively). The alteration at 
8 h was more remarkable (p = 0.003 and p = 0.003, respec-
tively). The alteration at 24 h was not significant, but FENa 
after 1 week significantly increased (p = 0.019) (Fig. 1b, c). 
The serum creatinine and serum sodium increased signifi-
cantly after 1 week (p = 0.012 and p = 0.002, respectively), 
and eGFR decreased similarly (p = 0.008) (Table 2). How-
ever, there were 7 cases in which serum creatinine level 
decreased. There were no differences in blood pressure, 
BNP, hANP, and ADH between the baseline and 1  week 
with tolvaptan treatment (Table 2).
We analyzed the relationship between body weight 
alteration and several parameters (Table  3). The 
Table 1  Clinical characteristics 
of patients
IQR interquartile range, n number, NYHA New York association criteria, CKD chronic kidney disease, ARB 
angiotensin II receptor blocker, ACEI angiotensin converting enzyme inhibitor, U-Na urine sodium excre-
tion, FENa fractional excretion of sodium, eGFR estimated glomerular filtration rate
Value
Age (median, IQR) 69 (60–76)
Sex (male) [n (%)] 15 (71.4)
Body weight (kg) (median, IQR) 62.6 (54.6–72.5)
Body mass index (kg/m2) (median, IQR) 24.8 (20.1–29.0)








Primary disease [n (%)]
 Benign nephropathy 10 (47.6)
 Diabetic nephropathy 7 (33.3)
 Polycystic kidney disease 1 (4.8)
 Microscopic polyangitis 1 (4.8)
 Membranous nephropathy 1 (4.8)
 Lupus nephritis 1 (4.8)





Furosemide (mg/day) (median, IQR) (n = 19) 120 (60–200)
Use of ARB, ACEI [n (%)] 12 (57.1)
Ejection fraction (%) (median, IQR) (n = 15) 71.8 (59.6–76.9)
Inferior vena cava diameter (mm) (median, IQR) (n = 14) 15.7 (11.0–21.0)
Average urinary volume for 3 days before administration (ml/day) (median, IQR) 975 (783–1350)
Urine gravity (n = 19) 1.011 (1.008–1.013)
U-Na (mEq/gCr) (median, IQR) (n = 20) 99.2 (60.9–145)
FENa (%) (median, IQR) (n = 20) 3.13 (1.5–5.16)
Serum creatinine (mg/dl) (median, IQR) 3.82 (3.48–5.08)
eGFR (ml/min/1.73 m2) (median, IQR) 11.6 (9.2–13.9)
Serum sodium (mEq/l) (median, IQR) 139 (136–142)
Serum osmolality (mOsm/kg) (median, IQR) (n = 18) 299 (296–309)
Brain natriuretic peptide (pg/ml) (median, IQR) 488.9 (89.3–599.1)
Atrial natriuretic peptide (pg/ml) (median, IQR) (n = 13) 104.0 (50.8–163.0)
Antidiuretic hormone (pg/ml) (median, IQR) (n = 9) 2.9 (1.4–3.5)
Urine osmolality (mOsm/kg) (median, IQR) (n = 19) 313 (269–352)
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alteration of body weight after 1  week correlated sig-
nificantly with the baseline urine osmolality (r = −0.479, 
p = 0.038), urine volume (r = −0.48, p = 0.028), and 
IVCD (r = −0.622, p = 0.017) (Fig.  2). The alteration of 
body weight did not correlated with the baseline and after 
body weight. Serum creatinine, eGFR, endocrine hor-
mone, and urea sodium excretion were not significantly 
correlated.
The increases in the serum sodium concentration 
were negatively associated with the basal sodium levels 
(r = −0.546, p = 0.01) (Fig. 3). The cases of hyponatremia 
were improved to the normal value.
Among 21 study participants, 2 patients discontinued 
tolvaptan treatment during the study periods because of 
liver dysfunction and cerebral infarction, respectively.
Discussion
In this study, we demonstrated that tolvaptan produced sig-
nificant diuretic effects and reduced body weight in CKD 
patients. The urine osmolality was also decreased sig-
nificantly. There was a slight increase in serum creatinine 
level, but improvement for hyponatremia was observed. 
The reduction of body weight after administration of 
tolvaptan was correlated with the baseline urine volume, 
urine osmolality, and the IVCD, but not with renal function 
in the study subjects.
We confirmed that body weight decreased and urine vol-
ume increased by tolvaptan in advanced stages of CKD. 
Although the increase of urine volumes seen in those 
patients were lower than those in patients with normal 
Table 2  Change of clinical 
parameters after administration 
of tolvaptan
IQR interquartile range, n number, eGFR estimated glomerular filtration rate
Parameter Baseline (median, IQR) 1 week (median, IQR) p value
Body weight (kg) 62.6 (54.6–72.5) 61.6 (47.7–70.9) < 0.001
Average urinary volume (ml/day) 975 (783–1350) 1426 (1079–1557) < 0.001
Systric blood pressure (mmHg) 136 (126–143) 130 (119–147) 0.852
Diastolic blood pressure (mmHg) 74 (64–78) 68 (64–76) 0.794
Urine gravity (n = 19) 1.011 (1.008–1.013) 1.009 (1.008–1.012) 0.172
Serum creatinine (mg/dl) 3.82 (3.48–5.08) 4.35 (3.74–5.45) 0.012
eGFR (ml/min/1.73 m2) 11.6 (9.2–13.9) 9.8 (8.9–12.6) 0.008
Serum sodium (mEq/l) 139 (136–142) 141 (138–143) 0.002
Brain natriuretic peptide (pg/ml) 488.9 (89.3–599.1) 337.0 (113.1–506.0) 0.117
Atrial natriuretic peptide (pg/ml) (n = 13) 104.0 (50.8–163.0) 99.9 (48.7–181.0) 0.576
Antidiuretic hormone (pg/ml) (n = 9) 2.9 (1.4–3.5) 4.2 (1.85–4.75) 0.735
Fig. 1  Alterations of urine parameters by tolvaptan treatment with 
CKD patients. a Urine osmolality decreases after 4  h (n = 17), and 
more remarkable at 8  h (n = 16). The effects on urine osmolality 
continued throughout the study periods. b Urinary sodium excre-
tion (U-Na; mEq/gCr) increased significantly after 4 h (n = 17), and 
more remarkable after 8 h (n = 17). c FENa changed similar to U-Na, 
but also increased significantly 1  week later (n = 20). *p < 0.05, 
**p < 0.01, ***p < 0.001
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renal function [10, 11], it is effective to delay introducing 
renal replacement therapy. Even in the advanced stages of 
CKD, tubule-interstitial functions were reported as being 
maintained to a certain degree, particularly in the collect-
ing ducts of the medullary area [12]. Collecting tubules 
are known as a low oxygen consumption tissue compared 
with the medullary thick ascending limb of Henle, which is 
the site of action of furosemide [13, 14], and is thought to 
be strong against hypoxic conditions. Thus, tolvaptan may 
work even if the kidney function decreased to the advanced 
stages of CKD. Furthermore, because tolvaptan is trans-
ported to collecting ducts without binding to proteins in 
blood, tolvaptan is not affected by serum or urine proteins 
levels as compared with furosemide [15–17]. It is also 
thought to be less susceptible to the glomerular filtration 
rate and urine flow, because it acts from the vascular side 
of principal cells of the collecting duct. Indeed, serum cre-
atinine and eGFR were not correlated with diuretic effects 
in our study. Thus, tolvaptan may show diuretic effects in 
furosemide-resistant cases such as in advanced stages of 
CKD. Natriuretic effects of co-administering diuretics (i.e., 
furosemide) may also be enhanced due to the improvement 
of renal congestion by tolvaptan [18, 19]. Urinary excretion 
of sodium and FENa increased after tolvaptan treatment 
in our study, suggesting that furosemide resistance was 
improved. Moreover, plasma arginine vasopressin has stim-
ulatory effects on epithelial Na-channel (ENaC)-mediated 
sodium reabsorption in the distal nephrons [20], and inhibi-
tion of  V2 receptors by tolvaptan decreases the ENaC activ-
ity and enhances excretion of sodium in urine [21].
Recent studies reported that increased expression of 
aquaporin-2 was observed in the epithelial cells of the col-
lecting ducts of tolvaptan responders [12]. However, it is 
still unclear what clinical factors are associated with diu-
retic effects and weight reduction. Therefore, we examined 
predictors of effects of tolvaptan, which are often measured 
routinely in clinical settings. We found that the baseline 
urine osmolality, urine volume, and IVCD negatively cor-
related with body weight reduction after tolvaptan treat-
ment. Urine osmolality was reported as a predictor of dis-
tinguishing responders from non-responders to tolvaptan 
in decompensated heart failure patients [22]. Similarly, a 
significant difference in the urine osmolalities before the 
tolvaptan treatment was observed between responders and 
non-responders in CKD patients [23]. The concentrated 
Table 3  Correlations of baseline parameters and body weight altera-
tion
rs Spearman’s rank correlation coefficient, n number, U-Na urine 
sodium excretion, FENa fractional excretion of sodium, eGFR esti-
mated glomerular filtration rate
Parameter rs p value




Furosemide (mg/day) −0.215 0.349
Average urinary volume (ml/day) −0.48 0.028
Ejection fraction (%) (n = 15) 0.066 0.815
Inferior vena cava diameter (mm) (n = 14) −0.622 0.017
Urine gravity (n = 19) −0.376 0.113
Urine osmolality (mOsm/kg) (n = 19) −0.479 0.038
U-Na (mEq/gCr) (n = 20) −0.263 0.282
FENa (%) (n = 20) −0.04 0.867
Serum creatinine 0.113 0.626
eGFR (ml/min/1.73 m2) −0.034 0.884
Serum sodium (mEq/l) −0.093 0.689
Serum osmolality (mOsm/kg) (n = 18) −0.236 0.345
Brain natriuretic peptide (pg/ml) (n = 20) −0.229 0.317
Atrial natriuretic peptide (pg/ml) (n = 13) −0.412 0.162
Antidiuretic hormone (pg/ml) (n = 9) −0.561 0.116
Fig. 2  Correlations between diuretic effects of tolvaptan and body weight in CKD patients. The alteration of body weight after 1 week nega-
tively correlated with the baseline urine osmolality (n = 19), urine volume (n = 21), and IVCD (n = 14)
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urine suggests that the function of collecting ducts remains. 
Moreover, when there was no or only mild tubule-intersti-
tial damage in the kidney biopsies, it has been reported that 
tolvaptan was effective even when glomerulosclerosis was 
present [12]. Thus, if the high urine osmolality remained, 
tolvaptan would demonstrate significant diuretic effects in 
cases with complicating renal failure. Apart from the urine 
osmolality, the baseline urine volume and IVCD also cor-
related with the alteration of body weight in this study. The 
high urine volume and enlarged IVCD suggest an increased 
intravascular fluid volume. Therefore, we estimate that diu-
retic effects are obtainable in these cases.
In cases of hyponatremia, the serum sodium concentra-
tion was markedly improved. Similar to our report, there 
was a study reporting that changes in serum sodium con-
centrations after tolvaptan treatment inversely correlated 
with their baseline values [24]. This study included a case 
with relative excess secretion of vasopressin in spite of 
hyponatremia (serum sodium 121 mEq/l, serum osmolality 
258  mOsm/kg, ADH 1.0  pg/ml). Furthermore, the serum 
sodium markedly increased in this case; the increase of 
serum sodium was 20 mEq/l within 1 week. The negative 
correlation between baseline serum sodium concentra-
tions and increments of serum sodium concentrations after 
tolvaptan treatment remained even if we excluded this case 
(r = −0.472, p = 0.036). Fortunately, the adverse event had 
not occurred in the case. However, we should pay atten-
tion to the doses of tolvaptan in the case of hyponatremia, 
because there is a risk of osmotic demyelination syndrome 
with rapid correction of serum sodium concentrations. As 
ADH secretion was enhanced in patients with heart failure 
[25], it is possible that cases with excess secretion of ADH 
are included in the study populations. For this reason, there 
may be a corrective effect for hyponatremia. Therefore, 
tolvaptan may be a suitable drug for combination treatments 
with diuretics in CKD patients with refractory chronic 
heart failure (CHF). On the other hand, hyponatremia was 
considered to be a factor of poor prognosis in cases with 
CKD and CHF [26], and such hyponatremic patients were 
known for having risks of incidental fall and bone fracture 
[27], which causes long-term hospitalization and deteriora-
tion of quality of life. Therefore, it is reasonable to choose 
tolvaptan for treating CKD with hyponatremia.
The serum creatinine concentration increased slightly in 
this study. However, there are several reports that tolvaptan 
may protect against renal function. Costello et al. reported 
increased renal blood flow after administration of tolvaptan 
among patients with heart failure as compared with placebo 
or furosemide [1]. It is also speculated that tolvaptan stimu-
lates neither the sympathetic activities nor renin–angioten-
sin–aldosterone (RAA) systems [28]. If tolvaptan is added 
to the treatment, there may be the advantage of reducing 
the dose of furosemide, which stimulates both sympathetic 
and RAA systems. In some clinical studies, serum creati-
nine and eGFR were reported not to be altered by tolvap-
tan treatment [15, 18, 24, 29]. In addition, the worsening 
renal function risk was lower with tolvaptan than conven-
tional treatment in patients with acute decompensated heart 
failure [29–31], and the effects on eGFR were similar to 
carperitide [32, 33]. Furthermore, it must be considered 
that lower eGFR was found to be a significant risk fac-
tor for a faster decline of eGFR [34]. In this study, there 
was a significant difference in the baseline ADH level 
between groups with increased and decreased serum cre-
atinine after tolvaptan treatment (p = 0.048). The baseline 
ADH was measured in 9 cases, and the ADH level in the 
group with decreased serum creatinine (n = 3) was higher 
than that with increased serum creatinine level (n = 6). The 
free water retention due to excessive secreted ADH might 
be related to worsen renal failure in CHF, and the block-
ade of vasopressin V2 receptor by tolvaptan might provide 
improvement of the renal function.
Two cases were not able to continue use of tolvaptan 
because of its side effects. One patient exhibited liver dys-
function. Similarly, in the study of patients with autosomal 
dominant polycystic kidney disease, it was also reported 
that patients receiving tolvaptan had an increased risk of 
alanine aminotransferase or aspartate aminotransferase 
level elevation [35]. The other patient developed cerebral 
infarction. The mild hemiplegia symptom developed on the 
fourth day, and a small infarction lesion was detected by 
CT examination. There is no report of cerebral infarction 
Fig. 3  Increases in the serum sodium concentration were negatively 
correlated with the basal sodium levels in non-parametric test (n = 21)
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associated with tolvaptan, even in the above clinical trials 
[35]. They were not fatal clinical conditions, but caution 
and accumulation of further cases are required.
This study has several limitations. As there were incon-
sistencies in the timing of cardiac echo (several days before 
administration, at the start of tolvaptan, etc), the CHF sta-
tus might not be evaluated precisely. Furthermore, this is 
a retrospective observational study with a relatively small 
number of patients. It is necessary to examine the plasticity 
in more cases to warrant the results. A prospective study 
in which patients are randomized to comparison groups 
with placebo or other diuretics is expected to confirm our 
results.
In conclusion, tolvaptan has diuretic effects in cases with 
complicated, advanced renal dysfunction corresponding to 
stage 3–5 CKD, and is also effective in correcting hypona-
tremia. As the baseline urine osmolality, urine volume, and 
IVCD correlated closely with the amount of reduction in 
body weight, they may be useful predictors for diuretic 
effects of tolvaptan. In cases of maintaining urine concen-
trating abilities, tolvaptan may be the treatment of choice 
for CKD patients with fluid retention.
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